
All

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Citalid Secures U.S. Patent for Automated Cyberattack Simulation Powering Its CRQ Platform
Citalid, the leading cyber risk quantification (CRQ) tech provider in Europe, today announced the grant of U.S. Patent No. 12,542,803 B2 for a proprietary automated cyberattack...

Obesity: The Microbiome at the Intersection of Nutrition and Pharma
In a groundbreaking report Microbiome & Obesity: A Seventure Perspective on the Next Healthcare
Frontier, Isabelle de Cremoux, CEO of Seventure Partners, analyzes the...

Zenniz Completes $6 Million Raise, Establishing USA HQ
Zenniz, the world's leading provider of smart tennis court solutions, successfully completed a new $6M USD funding round backed by multiple VC funds.
The investors...

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive...

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close...

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of...